ArticleGene therapy2013
Intrarectal administration of mCRAMP-encoding plasmid reverses exacerbated colitis in Cnlp(-/-) mice.
Article in Gene therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 46 citations in OpenAlex.
- Citrullination of CAMP exacerbating mucosal inflammation in inflammatory bowel disease.Precision clinical medicine · 2025Article
- Cathelicidin regulates goblet cell mucus secretion and mucus-associated proteins inGut microbes · 2025Article
- Anti-inflammatory and antibacterial effects of human cathelicidin active fragment KR-12 in the mouse models of colitis: a novel potential therapy of inflammatory bowel diseases.Pharmacological reports : PR · 2021Article
- Antimicrobial host defence peptides: functions and clinical potential.Nature reviews. Drug discovery · 2020Review
- Significance of LL-37 on Immunomodulation and Disease Outcome.BioMed research international · 2020Review
- Cathelicidins Modulate TLR-Activation and Inflammation.Frontiers in immunology · 2020Review
- Protective Effects of Protegrin in Dextran Sodium Sulfate-Induced Murine Colitis.Frontiers in pharmacology · 2019Article
- Cathelicidin-WA Facilitated Intestinal Fatty Acid Absorption Through Enhancing PPAR-γ Dependent Barrier Function.Frontiers in immunology · 2019Article
- The Critical Role of the Antimicrobial Peptide LL-37/ CRAMP in Protection of Colon Microbiota Balance, Mucosal Homeostasis, Anti-Inflammatory Responses, and Resistance to Carcinogenesis.Critical reviews in immunology · 2019Review
- High salt diet exacerbates colitis in mice by decreasing Lactobacillus levels and butyrate production.Microbiome · 2018Article
- Exogenous murine antimicrobial peptide CRAMP significantly exacerbates Ovalbumin-induced airway inflammation but ameliorates oxazolone-induced intestinal colitis in BALB/c mice.Human vaccines & immunotherapeutics · 2018Article
- MUC2 Mucin and Butyrate Contribute to the Synthesis of the Antimicrobial Peptide Cathelicidin in Response to Entamoeba histolytica- and Dextran Sodium Sulfate-Induced Colitis.Infection and immunity · 2017Article
- High therapeutic efficacy of Cathelicidin-WA against postweaning diarrhea via inhibiting inflammation and enhancing epithelial barrier in the intestine.Scientific reports · 2016Article
- Colonic MUC2 mucin regulates the expression and antimicrobial activity of β-defensin 2.Mucosal immunology · 2015Article
- Do antimicrobial peptides and complement collaborate in the intestinal mucosa?Frontiers in immunology · 2015Review
- Cathelicidin suppresses colon cancer development by inhibition of cancer associated fibroblasts.Clinical and experimental gastroenterology · 2015Article
- Antimicrobial peptides and gut microbiota in homeostasis and pathology.EMBO molecular medicine · 2013Review
- Cathelicidin protects against Helicobacter pylori colonization and the associated gastritis in mice.Gene therapy · 2013Article
- Cathelicidin a potential therapeutic peptide for gastrointestinal inflammation and cancer.World journal of gastroenterology · 2013Review
- Cathelicidin gene therapy: a new therapeutic option in ulcerative colitis and beyond?Gene therapy · 2013Article
Corrections and comments
- Commented on by
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cathelicidin is a pleiotropic host defense peptide secreted by epithelial and immune cells. Whether endogenous cathelicidin is protective against ulcerative colitis, however, is unclear. Here we sought to delineate the role of endogenous murine cathelicidin (mCRAMP) and the therapeutic efficacy of intrarectal administration of mCRAMP-encoding plasmid in ulcerative colitis using dextran sulfate sodium (DSS)-challenged cathelicidin-knockout (Cnlp(-/-)) mice as a model. Cnlp(-/-) mice had more severe symptoms and mucosal disruption than the wild-type mice in response to DSS challenge. The tissue levels of interleukin-1β and tumor necrosis factor-α, myeloperoxidase activity and the number of apoptotic cells were increased in the colon of DSS-challenged Cnlp(-/-) mice. Moreover, mucus secretion and mucin gene expression were impaired in Cnlp(-/-) mice. All these abnormalities were reversed by the intrarectal administration of mCRAMP or mCRAMP-encoding plasmid. Taken together, endogenous cathelicidin may protect against ulcerative colitis through modulation of inflammation and mucus secretion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.